Articles tagged with Glioblastoma Cells
A study published in Cell Reports found that altering the levels of microRNA miR-128 can induce a more homogeneous subtype of glioblastoma cells, making them more responsive to treatment. This discovery opens the door for using miR-128 as a therapeutic agent.
Scientists have pinpointed two molecules, FOXG1 and SOX2, that drive glioblastoma cells' rapid division and prevent specialization. These findings could lead to the development of new therapies targeting these molecules to slow or stop tumour growth.
Researchers at Uppsala University discovered a correlation between brain tumor cell origin and its growth rate, malignancy, and response to cancer drugs. The study found that tumors originating from immature neural stem cells were more aggressive and less sensitive to treatment than those from differentiated glial cells.
A study suggests targeting the RAD51 protein could increase the effectiveness of radiotherapy in killing off glioblastoma cells, a subgroup of brain tumour cells that are resistant to treatment. Glioblastoma is the most common and aggressive type of primary brain tumour in adults, with a poor prognosis.
A new laboratory test developed by Johns Hopkins Medicine accurately clocks the 'speed' of human brain tumor cell movement, which may predict how quickly and aggressively a given cancer might lethally spread. The assay has been tested on 14 glioblastoma patients and showed promising results in predicting clinical outcomes.
A gene known as OSMR plays a key role in driving the growth of glioblastoma tumors, according to a new study. Researchers discovered that by disabling OSMR, glioblastoma cells lose their ability to form tumors in mice, suggesting a potential target for treatments.
Researchers identified a critical immunotherapy target by marking dysfunctional regulatory T cells in glioblastoma multiforme patients. Anti-PD1 therapies may drive further regulatory T cell dysfunction, suggesting potential treatment benefits.
Researchers analyzed myeloid lineage immune cells in glioblastoma patients, revealing non-polarized cell state and potential therapeutic strategy. The study suggests stimulating these cells to adopt an anti-tumor identity may be effective.
Researchers discovered a common molecular alteration in glioblastoma that prevents cells from degrading genetic material during apoptosis. This defect is related to an enzyme called endonuclease DFF40/CAD, which is downregulated and improperly located inside tumour cells.
Researchers at UT-Arlington developed a novel cancer cell detection method based on real-time cell behavior tracking, leveraging the unique dancing behavior of cancer cells on engineered surfaces. This technology has potential to serve as an additional modality for identifying tumor cells from blood samples or biopsy specimens.
Researchers describe a new treatment option for glioblastoma multiforme, targeting malignant cells while leaving healthy cells alive with high-frequency pulsed electric fields. The therapy has shown promise in killing tumor cells by disrupting cell membranes and causing nuclear collapse.
Researchers from Virginia Tech Carilion Research Institute and clinicians have discovered a way to sensitize human glioblastoma cells to chemotherapy, offering new hope for patients with aggressive brain cancer. The breakthrough involves inhibiting connexin 43, a protein that facilitates cell signaling in damaged cells.
Geneticists identified double minutes in glioblastoma cells with specific oncogenes, which amplify malignancy and give cancer cells an adaptive edge. The presence of these mini-chromosomes is detected in most aggressive cancers.
Researchers have discovered that invading glioblastoma cells hijack cerebral blood vessels to extract nutrients, damaging the brain's protective barrier and potentially leading to new cancer treatments. This finding could enable earlier delivery of anti-invasive agents to attack tumor cells.
A team of researchers identified four transcription factors that distinguish glioblastoma stem cells from more differentiated tumor cells. These factors were found to be active in 2-7% of human glioblastoma cells and could be targeted by new therapeutic approaches.
Researchers at Karolinska Institutet have discovered a new mechanism to kill glioblastoma cells using Vacquinol-1, which causes uncontrolled vacuolization leading to cell explosion and necrosis. This approach may lead to new cancer treatments, potentially working for other cancer diseases.
Genomic deletions in cancer cells eliminate tumor-suppressor genes, but also expose vulnerabilities to other essential genes. Researchers found that targeting the redundant function of these genes can kill malignant cells. The study identified ENO1 and ENO2 as key targets for therapy.
Researchers found that downregulation of CD97 gene expression by suppressing Wilms tumor 1 protein results in reduced cellular invasiveness exhibited by glial tumor cells, correlating with glioma cell invasiveness and proposed as a new target for anti-glioma therapies.
Researchers at Stanford Medicine have discovered a gene deletion in up to one-fourth of glioblastoma cases, a type of brain cancer with poor survival prospects. The deletion contributes to tumor growth, resistance to therapy, and worsens patient outcomes.
Researchers at Wake Forest University Baptist Medical Center have identified a way to target and destroy Glioblastoma multiforme (GBM) cells without harming healthy cells. The breakthrough allows for new possibilities in cancer research, potentially leading to less toxic and invasive treatments.
Researchers found that a deficiency in tumor suppressor gene p53 leads to glioblastoma, a highly aggressive type of brain cancer. The study suggests that targeting the subventricular zone, where neural stem cells reside, may improve treatment outcomes and enable early detection.
A study conducted by Michigan Medicine scientists found that a deficiency in the p53 gene in the brain leads to glioblastoma, a type of adult brain cancer. The researchers discovered that neural stem cells in the subventricular zone may be the origin of this aggressive cancer, suggesting a new target for treatment and early screening.
Researchers at Duke University have identified a receptor on human glioblastoma cells that may be an appropriate target for therapies. Activation of the neurokinin 1 receptor leads to increased cell growth, but blocking this activity can reduce cell death and potentially stall cancer growth.
Researchers found that RTK inhibitors can be less effective in treating glioblastoma multiforme (GBM) due to cell death inhibition. Combining RTK and IAP inhibitors showed promise in inducing apoptosis in GBM cells, with enhanced efficacy in orthotopic mouse models.
Researchers used a natural protein called BMP4 to inhibit glioblastoma, a deadly human brain cancer, in mice by targeting stem-cell-like clusters that feed the cancer. The treatment was successful in stopping cancer growth and improving survival rates.
A study published in Clinical Cancer Research shows that Herstatin blocks the growth of brain tumors by inhibiting signaling inside tumor cells. The treatment has shown promise as a viable alternative to traditional brain tumor treatment methods, particularly for glioblastoma, the most deadly form of brain cancer.